Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

US Zika Pregnancy Registry

If you have questions about a possible infection or diagnosis

If families would like to speak to someone about a possible Zika virus infection or diagnosis during pregnancy and risk to the baby, please contact MotherToBaby. MotherToBaby experts are available to answer questions in English or Spanish by phone or chat. The free and confidential service is available Monday - Friday from 8am - 5pm (local time). To reach MotherToBaby:

  • Call 1-866-626-6847
  • Chat live or send an email through the MotherToBaby website

Zika virus infection during pregnancy can cause microcephaly and other severe fetal brain defects. Infection during pregnancy has also been linked to adverse outcomes including pregnancy loss, and eye defects, hearing loss, and impaired growth in infants. Despite these observations, many questions remain about the risks of Zika virus infection during pregnancy. Information about the timing, absolute risk, and spectrum of outcomes associated with Zika virus infection during pregnancy is needed to direct public health action related to Zika virus and guide testing, evaluation, and management.

To understand more about Zika virus infection, CDC established the US Zika Pregnancy Registry and is collaborating with state, tribal, local, and territorial health departments to collect information about pregnancy and infant outcomes following laboratory evidence of Zika virus infection during pregnancy. The data collected through this registry will be used to update recommendations for clinical care, to plan for services for pregnant women and families affected by Zika virus, and to improve prevention of Zika virus infection during pregnancy. 

  • If you are a healthcare provider or health department and you have questions about the registry, please email or call 770-488-7100 and ask for the Zika Pregnancy Hotline.

Eligibility for the Registry

 People who are eligible for inclusion in the Registry include

  • Pregnant women in the United States and US territories (with the exception of Puerto Rico) with laboratory evidence* of possible Zika virus infection (regardless of whether they have symptoms) and periconceptionally, prenatally, or perinatally exposed infants born to these women.
  • Infants with laboratory evidence* of possible congenital Zika virus infection (regardless of whether they have symptoms) and their mothers.

Health Departments: How to Participate

State, tribal, local, and territorial health departments can participate in the US Zika Pregnancy Registry. They can

  • Identify pregnant women and infants eligible for Zika virus testing in accordance with state or CDC guidelines.
  • Coordinate testing at a state public health laboratory or CDC for those eligible.
  • Report cases of pregnant women in the United States and US territories (with the exception of Puerto Rico)  with laboratory evidence* of possible Zika virus infection (regardless of whether they have symptoms) and periconceptionally, prenatally, or perinatally exposed infants born to these women.
  • Report infants with laboratory evidence* of possible congenital Zika virus infection (regardless of whether they have symptoms) and their mothers.
  • Collect enhanced surveillance data about pregnant women and their infants who are eligible for the Registry.
  • Work with CDC to determine state-specific methods for collecting and sharing data.

Healthcare Providers: How to Participate

CDC and state, tribal, local, and territorial health departments request that healthcare providers participate in the US Zika Pregnancy Registry.

Obstetric healthcare providers can:

  • Report information to their state, tribal, local, or territorial health department for pregnant women in the United States and US territories (with the exception of Puerto Rico) with laboratory evidence* of possible Zika virus infection (regardless of whether they have symptoms) and periconceptionally, prenatally, or perinatally exposed infants born to these women.
  • Report information to their state, tribal, local, or territorial health department for infants with laboratory evidence* of possible congenital Zika virus infection (regardless of whether they have symptoms) and their mothers.
  • Collect pertinent clinical information about pregnant women and their infants on the Pregnancy and Zika Virus Disease Surveillance forms.
  • Provide the information to state, tribal, local or territorial health departments or directly to CDC registry staff if asked to do so by local health officials.
  • Notify state, tribal, local, or territorial health department staff or CDC registry staff of adverse events (e.g., spontaneous abortion, termination of pregnancy).

Pediatric healthcare providers can:

  • Report information to their state, tribal, local, or territorial health department for infants with laboratory evidence* of possible congenital Zika virus infection (regardless of whether they have symptoms) and their mothers.
  • Collect pertinent clinical information about infants born to women with laboratory evidence of Zika virus infection or infants with congenital Zika virus infection.
  • Provide the information to state, tribal, local or territorial health departments or directly to CDC registry staff if asked to do so by local health officials.
  • Notify state, tribal, local, or territorial health department staff or CDC registry staff of adverse events (e.g., perinatal or infant deaths).

Healthcare providers practicing in Puerto Rico should report information to the Puerto Rico Zika Active Pregnancy Surveillance System (ZAPSS) rather than to the US Zika Pregnancy Registry.


*Laboratory evidence of possible Zika virus infection for the US Zika Pregnancy Registry is defined as:

  • Recent Zika virus infection detected by Zika RNA nucleic acid test (NAT) (e.g., real-time reverse transcription polymerase chain reaction [rRT-PCR]): 
    • Zika virus RNA detected by NAT on any maternal or fetal/infant clinical specimen (e.g., serum, urine, whole blood, cerebrospinal fluid, amniotic fluid, cord blood, saliva, placenta, umbilical cord tissue, placental membranes, or fetal tissue)
  • Recent Zika virus infection or recent flavivirus infection detected by serologic tests of maternal or infant serum or cerebrospinal fluid 
    • Zika virus IgM positive or equivocal AND Zika virus plaque reduction neutralization test (PRNT) titer ≥10, (regardless of dengue virus PRNT value) OR
    • Zika virus IgM positive AND Zika virus PRNT not performed in following state, tribal, local, or territorial health department protocol, OR
    • Zika virus IgM negative AND dengue virus IgM positive or equivocal AND Zika virus PRNT titer ≥10 (regardless of dengue virus PRNT titer)
    • These inclusion criteria are intentionally broad because of the known cross-reactivity in IgM testing and inability to distinguish between Zika and dengue virus through the use of PRNT.
    • If maternal Zika virus IgM and dengue virus IgM are both negative, and maternal PRNT was performed per jurisdictional protocol with Zika virus PRNT titer ≥10, additional testing is needed to meet inclusion criteria. For example, if maternal testing is performed >12 weeks from possible Zika virus exposure and maternal IgM testing is negative with Zika virus PRNT titer ≥10, the mother-infant pair would be included if the infant had Zika virus IgM positive or equivocal, Zika virus RNA or antigen detected, or Zika virus cultured. 
  • Zika virus infection confirmed by other tests in any maternal or fetal/infant clinical specimen (e.g., serum, urine, whole blood, cerebrospinal fluid, amniotic fluid, cord blood, saliva, placenta, umbilical cord tissue, placental membranes, or fetal tissue): 
    • Culture of Zika virus
    • Detection of Zika virus antigen

Fact Sheets

Top